ImClone Initiates Enrollment for Phase I/II Pancreatic Cancer Trials
Posted on: Wednesday, 21 May 2008, 09:00 CDT
ImClone Systems has announced that the initial stage of a series of Phase I/II clinical trials of IMC-A12 in patients with advanced pancreatic cancer has opened for patient enrollment.
The Southwest Oncology Group (SWOG), a cancer network sponsored by the National Cancer Institute (NCI), is evaluating IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in a small Phase I study immediately followed by a much larger randomized Phase II trial.
The initial 6-12 patient Phase I study will evaluate the side effects and recommend a dose of IMC-A12 administered in combination with gemcitabine and erlotinib, an approved regimen used to treat patients with advanced-stage pancreatic cancer. Immediately upon determination of a recommended Phase II dose for IMC-A12 combined with gemcitabine and erlotinib, a Phase II multicenter study will begin.
In the much larger Phase II study, previously untreated patients with advanced pancreatic cancer will be randomized to treatment with either IMC-A12 in combination with gemcitabine and erlotinib or the gemcitabine-erlotinib regimen without IMC-A12. Based on supportive preclinical data indicating favorable anticancer activity when IMC-A12 and inhibitors of the epidermal growth factor receptor, such as cetuximab and erlotinib, are combined, the principal objective of this Phase II study is to evaluate the efficacy of IMC-A12 plus gemcitabine and erlotinib.
In addition to this Phase II study of IMC-A12 in pancreatic cancer patients, Phase II studies of IMC-A12 in patients with advanced prostate, colorectal and liver cancers have begun to enroll patients, and a series of Phase I/II studies evaluating IMC-A12 in pediatric patients with advanced malignancies has opened for patient enrollment.
Source: Datamonitor
Related Articles
- Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
- ImClone Systems Initiates Enrollment for Phase II Breast Cancer Study
- Cytopia Initiates Enrollment for Second Phase II Brain Cancer Study
- ImClone Systems Initiates Enrollment in Phase II Prostate Cancer Study
- Merck Initiates Phase III Gastric Cancer Study
- CuraGen Initiates Phase II Breast Cancer Study
- OncoGenex Reports Positive Results From Phase II Prostate Cancer Study
- Progen Presents Positive Data From Phase II Liver Cancer Study
- Encouraging Preliminary Data From TNFerade(TM) Phase II Rectal Cancer Study Presented at ASTRO Meeting
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
 |
 |
User Comments (0)
RSS Feeds